Cetuximab-based Zybody

Cetuximab-based Zybody refers to a next-generation, engineered antibody platform derived from cetuximab, a chimeric (mouse/human) IgG1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Cetuximab itself is approved for the treatment of metastatic colorectal cancer and squamous cell carcinoma of the head and neck. It works by binding to EGFR on tumor cells, blocking ligand-induced activation and downstream signaling pathways involved in cell proliferation, survival, angiogenesis, and metastasis. Additionally, as an IgG1 antibody, it can mediate immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC)[2][5][6]. The "Zybody" platform typically refers to antibodies engineered to have additional specificities or functionalities beyond those of standard monoclonal antibodies; however, specific details about "cetuximab-based Zybody" are not widely published in current literature.

Other names

cetuximab-based Zybody